---
title: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39651791/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241209184143&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Adding blinatumomab to combination chemotherapy in patients
  with newly diagnosed childhood standard-risk B-cell ALL of average or high risk
  of relapse significantly improved disease-free survival. (Funded by the National
  Institutes of Health and others; AALL1731 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or high risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of Health and others; AALL1731 ClinicalTrials.gov number, ...